Diagnosis and treatment of chronic obstructive pulmonary disease (COPD)
Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a post-translational modification. In some embodiments, the histone protein is H2B, H3, H3.3 or H4. Kits for practicing the methods of diagnosis and/or staging are provided as well. Further provided is a method for treating COPD.
1. A method of treating COPD, the method comprising:
(a) detecting at least one H3.3 post-translational modification in a sample from a patient, wherein the at least one modification comprises:
lysine acetylation at position 10,
lysine acetylation at position 15,
dimethylation of lysine at position 28,
dimethylation of lysine at position 38,
dimethylation of arginine at position 43,
mono-methylation of lysine at position 80,
trimethylation of lysine at position 80,
mono-methylation of aspartate at position 107,
nitrosylation of cysteine at position 111,
simultaneous acetylation and mono-methylation of lysine at position 116, or
oxidation of methionine at position 121,
of SEQ ID NO:1; and
(b) administering a COPD treatment to said patient.
2. The method according to claim 1 wherein the COPD treatment comprises administering an agent that degrades an H3.3 protein, targets an H3.3 protein for degradation, inhibits the function of H3.3 or reduces the likelihood of toxicity caused by H3.3.
3. The method of claim 1 , wherein the sample is a nuclear lung extract.
4. The method of claim 1 wherein said post-translational modification is detected by mass spectrometry or by immunoassay.
5. The method of claim 1 wherein lysine acetylation at position 10 is detected.
6. The method of claim 1 wherein lysine acetylation at position 15 is detected.
7. The method of claim 1 wherein dimethylation of lysine at position 28 is detected.
8. The method of claim 1 wherein dimethylation of lysine at position 38 is detected.
9. The method of claim 1 wherein dimethylation of arginine at position 43 is detected.
10. The method of claim 1 wherein mono-methylation of lysine at position 80 is detected.
11. The method of claim 1 wherein trimethylation of lysine at position 80 is detected.
12. The method of claim 1 wherein mono-methylation of aspartate at position 107 is detected.
13. The method of claim 1 wherein nitrosylation of cysteine at position 111 is detected.
14. The method of claim 1 wherein simultaneous acetylation and mono-methylation of lysine at position 116 is detected.
15. The method of claim 1 wherein oxidation of methionine at position 121 is detected.
16. The method of claim 1 wherein at least two of said post-translational modifications are detected.
17. A method of treating COPD, the method comprising:
(a) determining the level of an H3.3 protein having acetylation of lysine at position 24 of SEQ ID NO:1 from a test sample of a patient;
(b) comparing the level of said H3.3 protein in the test sample with the level of said H3.3 protein in a control sample;
(c) determining an elevated level of said H3.3 protein in the test sample as compared to the level of said H3.3 protein in the control sample; and
(d) administering a COPD treatment to said patient.
18. The method of claim 17 wherein said post-translational modification is detected by mass spectrometry or by immunoassay.
19. The method of claim 17 , wherein the sample is a nuclear lung extract.
20. The method according to claim 17 wherein the COPD treatment comprises administering to the patient an agent that degrades an H3.3 protein, targets an H3.3 protein for degradation, inhibits the function of H3.3 or reduces the likelihood of toxicity caused by H3.3.
21. The method of claim 17 wherein the control sample is from a healthy person without COPD, from an ex-smoker without COPD, or from a Global Initiative for Chronic Obstructive Lung Disease (GOLD) 0 patient.
22. A method of treating COPD comprising:
administering a COPD treatment to a patient in which a biological fluid test sample or biological tissue test sample from the patient has been determined to contain an H3.3 protein having at least one post-translational modification comprising:
lysine acetylation at position 10,
lysine acetylation at position 15,
dimethylation of lysine at position 28,
dimethylation of lysine at position 38,
dimethylation of arginine at position 43,
mono-methylation of lysine at position 80,
trimethylation of lysine at position 80,
mono-methylation of aspartate at position 107,
nitrosylation of cysteine at position 111,
simultaneous acetylation and mono-methylation of lysine at position 116, or
oxidation of methionine at position 121,
of SEQ ID NO:1.
23. The method of claim 22 wherein said post-translational modification has been detected by mass spectrometry or by immunoassay.
24. The method of claim 22 wherein lysine acetylation at position 10 has been detected in the test sample.
25. The method of claim 22 wherein lysine acetylation at position 15 has been detected in the test sample.
26. The method of claim 22 wherein dimethylation of lysine at position 28 has been detected in the test sample.
27. The method of claim 22 wherein dimethylation of lysine at position 38 has been detected in the test sample.
28. The method of claim 22 wherein dimethylation of arginine at position 43 has been detected in the test sample.
29. The method of claim 22 wherein mono-methylation of lysine at position 80 has been detected in the test sample.
30. The method of claim 22 wherein trimethylation of lysine at position 80 has been detected in the test sample.
31. The method of claim 22 wherein mono-methylation of aspartate at position 107 has been detected in the test sample.
32. The method of claim 22 wherein nitrosylation of cysteine at position 111 has been detected in the test sample.
33. The method of claim 22 wherein simultaneous acetylation and mono-methylation of lysine at position 116 has been detected in the test sample.
34. The method of claim 22 wherein oxidation of methionine at position 121 has been detected in the test sample.
35. The method of claim 22 wherein at least two of said post-translational modifications have been detected.
36. A method of treating COPD comprising:
administering a COPD treatment to a patient in which a biological fluid test sample or biological tissue test sample from the patient has been determined to contain an elevated level of an H3.3 protein having acetylation of lysine at position 24 of SEQ ID NO:1, compared to the level of the said H3.3 protein in a control sample.
37. The method of claim 36 wherein the level of said H3.3 protein having acetylation of lysine at position 24 of SEQ ID NO:1 has been determined by mass spectrometry or by immunoassay.